Tata Elxsi has launched AnaTel, an AI-native software development platform designed for healthcare and medical technology companies, to reduce development cycle times by up to 60%. Co-developed with OpenAna, the platform addresses rising regulatory expectations by embedding autonomous AI agents directly into engineering workflows. AnaTel made its debut at DeviceTalks Boston 2026 on May 27, 2026.

The platform targets operational challenges in medtech software teams, where regulatory bodies like the FDA and Europe's MDCG require rigorous lifecycle documentation and traceability. AnaTel operates across the full AI-Driven Software Delivery Lifecycle, generating code, documentation, test cases, and regulatory artifacts. It supports eSTAR-aligned submission preparation and is expected to reduce SaMD development timelines from eight weeks to 72 hours.

Platform Capabilities

AnaTel functions as a configurable AI software team, drawing on a Healthcare and Life Sciences expert agent fine-tuned for medtech regulatory and engineering contexts. Key features include:

• Autonomous AI agents embedded in engineering workflows
• Generation of regulatory-grade documentation and test cases
• Support for requirements traceability matrices and audit trails
• Reduction in change assessment timelines

Strategic Partnership

The platform was developed through STEP.UP, Tata Elxsi's co-innovation program for deep-tech companies. Tata Elxsi contributes design-led engineering and domain expertise, while OpenAna provides its platform of autonomous engineers.

Sreevatsa Sahasranaman, Senior Vice President and Head, Healthcare and Life Sciences, Tata Elxsi, stated that the platform accelerates regulatory-ready software engineering while keeping experts in control. Rajiv Sondhi, Chief Executive Officer of OpenAna, highlighted the partnership's focus on lifecycle traceability and safety in demanding domains.

Tata Elxsi has launched ViTel, a Material Intelligence solution for medical device manufacturers co-developed with Viridium AI. The solution aims to help manufacturers protect margins, accelerate sourcing and engineering decisions, and stay ahead of compliance through AI-powered material intelligence. ViTel is being formally introduced at DeviceTalks Boston 2026.

Medical device manufacturers face challenges where material decisions affect margin, resilience, product velocity, and market access. Critical product knowledge is often buried across BOMs, supplier documents, ERP and PLM systems, and expert teams. This fragmentation makes every new regulation or customer requirement a costly manual exercise.

ViTel addresses this by creating a reusable Material Intelligence layer across the enterprise. It helps teams identify material and supplier dependencies, assess country-of-origin and sourcing exposure, evaluate alternatives, and understand where product or material risks affect cost, continuity, or market access. The solution is powered by Viridium AI's Knowledge Cloud, Chemical Digital Twin, and science-constrained AI models.

The solution transforms scattered enterprise data into a living product-material knowledge graph connecting products, parts, materials, chemicals, suppliers, regulations, and evidence. ViTel draws on tata elxsi 's three decades of Med-Tech engineering and regulatory expertise. This knowledge has been embedded into how the solution reasons about material risk, compliance, and sourcing decisions.

Sreevatsa Sahasranaman, Senior Vice President and Head, Healthcare and Life Sciences, Tata Elxsi, stated that ViTel brings Material Intelligence directly into product and compliance workflows. He noted that this helps customers make faster, more confident decisions across sourcing, engineering, quality, and regulatory readiness.

Niraj Deo, Chief Executive Officer, Viridium AI, said the company was built to help manufacturers understand the material DNA of their products. He added that digitizing product and material knowledge creates a reusable enterprise asset for margin, sourcing, engineering, quality, and regulatory decisions.

ViTel is co-developed through STEP UP, Tata Elxsi's co-innovation program for high-potential deep-tech companies. Muthusamy Selvaraj, VP, Innovation and Partnerships, Healthcare and Life Sciences, Tata Elxsi, emphasized that the partnership ensures accountability for the outcome.